AgaMatrix, Inc.: Series C $23.7M

AgaMatrix (Salem, NH) maker of blood glucose monitoring systems that provide results to help users better manage their diabetes closed a $23.7M Series C financing. Participants include Ferrer Freeman & Co.

PeptImmune, Inc.: Series D $8.2M

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Ventures and Silicon Valley Bank Capital.

Pervasis Therapeutics, Inc.: Series B $9.75M

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

Aushon Biosystems, Inc.: Series B $7.0M

Aushon Biosystems (Burlington, MA) provides advanced microarray technologies to life science research, drug discovery, development and clinical diagnostics closed on a $4M traunche $7M Series B. Participant was North Bridge Venture Partners.

Cara Therapeutics, Inc.: Series C $24M

Cara Therapeutics (Tarrytown, NY) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation has closed a $24M Series C financing. Investors included Scottish Widows Investment Partnership, Mitsubishi International Corporation, MVM Life Science Partners, Alta Partners and Ascent Biomedical Ventures.

CircuLite, Inc.: Series B $20M

CicuLite (Hackensack, NJ) a medical device company focused on the development of a proprietary circulatory assist technology for the management of chronic heart failure, closed a $20M Series B. Investors included Forbion Capital Partners, Oxford Biosciences Partners, Foundation Medical Partners, and SB Life Science Ventures.

Microbia, Inc.: Series F $50M

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

Critical Biologics, Corp.: Series A $7M

Critical Biologics (Cambridge, MA) developer of therapeutics for critical-care patients with low plasma gelsolin, has raised $7 million in Series A funding from Morningside Ventures.

BioBehavioral Diagnostics: Series A $8.5M

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

Locus Pharma, Inc.: Series D $30.2M

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.